SECUKINUMAB: IL-17A INHIBITION TO TREAT PSORIATIC ARTHRITIS

被引：7

作者：

Speeckaert, R. ^{[1
]}

van Geel, N. ^{[1
]}

Lambert, J. ^{[1
]}

Claeys, L. ^{[2
]}

Delanghe, J. R. ^{[3
]}

Speeckaert, M. M. ^{[2
]}

机构：

[1] Ghent Univ Hosp, Dept Dermatol, De Pintelaan 185, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Dept Nephrol, Ghent, Belgium

[3] Ghent Univ Hosp, Dept Clin Chem, Ghent, Belgium

来源：

DRUGS OF TODAY | 2016年 / 52卷 / 11期

关键词：

bDMARDs; IL-17A; Psoriatic arthritis; Secukinumab; Monoclonal antibodies; Psoriasis; COLLAGEN-INDUCED ARTHRITIS; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; RANDOMIZED CONTROLLED-TRIAL; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; CARTILAGE DESTRUCTION; JOINT INFLAMMATION; PLAQUE PSORIASIS; BONE EROSION; EULAR RECOMMENDATIONS;

D O I：

10.1358/dot.2016.52.11.2526754

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1 kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials.

引用

页码：607 / 616

页数：10

共 50 条

[1] Dual inhibition of IL-17A and IL-17F in psoriatic disease
Iznardo, Helena
Puig, Lluis
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
[2] Secukinumab for the treatment of psoriatic arthritis
Hansen, Renata Baronaite
Kavanaugh, Arthur
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (10) : 1027 - 1036
[3] Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis
Ali, Zara
Matthews, Raymond
Al-Janabi, Ali
Warren, Richard B.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (10) : 1073 - 1081
[4] Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, Philip J.
McInnes, Iain B.
Kirkham, Bruce
Kavanaugh, Arthur
Rahman, Proton
van der Heijde, Desiree
Landewe, Robert
Nash, Peter
Pricop, Luminita
Yuan, Jiacheng
Richards, Hanno B.
Mpofu, Shephard
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (14) : 1329 - 1339
[5] IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis
Krueger, James G.
Wharton, Keith A., Jr.
Schlitt, Thomas
Suprun, Maria
Torene, Rebecca I.
Jiang, Xiaoyu
Wang, Claire Q.
Fuentes-Duculan, Judilyn
Hartmann, Nicole
Peters, Thomas
Koroleva, Irina
Hillenbrand, Rainer
Letzkus, Martin
Yu, Xiaojing
Li, Yue
Glueck, Anton
Hasselberg, Anke
Flannery, Brian
Suarez-Farinas, Mayte
Hueber, Wolfgang
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (03) : 750 - 763
[6] A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
Pelechas, Eleftherios
Memi, Tereza
Voulgari, Paraskevi V.
Drosos, Alexandros A.
RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 509 - 513
[7] A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
Eleftherios Pelechas
Tereza Memi
Paraskevi V. Voulgari
Alexandros A. Drosos
Rheumatology and Therapy, 2017, 4 : 509 - 513
[8] A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis
Qi, Jianying
Kan, Fangming
Ye, Xianlong
Guo, Mo
Zhang, Yu
Ren, Guiping
Li, Deshan
INTERNATIONAL IMMUNOPHARMACOLOGY, 2012, 14 (04) : 770 - 778
[9] Celastrol regulates psoriatic inflammation and autophagy by targeting IL-17A
Park, Aeri
Heo, Tae-Hwe
BIOMEDICINE & PHARMACOTHERAPY, 2024, 172
[10] A Review of the Use of Secukinumab for Psoriatic Arthritis
Patel, Nupur U.
Vera, Nora C.
Shealy, Emily Rose
Wetzel, Margaret
Feldman, Steven R.
RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 233 - 246

← 1 2 3 4 5 →